With Eli Lilly's recent acquisition of Verve Therapeutics and its PCSK9 candidate, delve into what the target represents.

Please provide your email address to receive an email when new articles are posted on . PCSK9 inhibitor prescriptions are rejected by insurers at a higher rate vs. other guideline-indicated ...

PHILADELPHIA -- A novel anti-PCSK9 monoclonal antibody with a distinctive longer duration of action reduced cholesterol and other lipids in the phase III REMAIN-2 trial. Recaticimab showed long-term ...

Please provide your email address to receive an email when new articles are posted on . Spatz, an associate professor of cardiology and epidemiology at Yale University School of Medicine, discussed ...

Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window ATLANTA -- A novel PCSK9 inhibitor safely reduced LDL ...

While currently available PCSK9 inhibitor medications to lower cholesterol must be administered every few weeks by injection, a new, investigational PCSK9 inhibitor called recaticimab safely lowered ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced plans to present new research from ...

WASHINGTON, DC — In order to be cost-effective for patients, providers, and payers, the new proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors would need to cost around $2400 per year, a mark ...

An investigational drug called lerodalcibep lowered low-density lipoprotein (LDL) cholesterol, or “bad” cholesterol, by 50% or more, a new study showed. The year-long clinical trial included people ...

BLOOMFIELD, Conn.--(BUSINESS WIRE)--Cigna (NYSE: CI) has entered into new value-based contracts with both Amgen and Sanofi/Regeneron for their PCSK9 inhibitors for commercial business. The contracts ...

New late-breaking clinical trial data presented at ACC and published simultaneously in JACC show benefit of investigational medicine AZD0780 on top of standard of care WILMINGTON, Del.--(BUSINESS WIRE ...